

# Managing Chronic Graft-Versus-Host Disease while living with Leukemia


Kehinde Adekola MD, MS

Associate Professor of Medicine Division of Hematology-Oncology Medical Director, Hem-Onc Stem Cell Transplant Unit Northwestern Medicine

## • No disclosures








Appelbaum FR. N Engl J Med 2007;357:1472-1475.




#### Number of HCTs in the US Reported to CIBMTR by Transplant Type






& MARROW TRANSPLANT RESEARCH

#### Number of HCTs by Indications in the US, 2020





#### Number of Allogeneic HCTs in the US by Donor Type





Abbreviations - MRD: Matched related donor, MUD: Matched unrelated donor, Haplo: Haploidentical donor (includes all mismatched related donors), MMUD: Mismatched unrelated donor, CB: Cord blood 3





#### Total 25,092,358 donors

-24,489,329 unrelated donors

-603,029 CBU


#### •74 stem cell donor registries from 53 countries

#### •49 cord blood banks from 33 countries






## Number of Allogeneic HCTs for Acute Myelogenous Leukemia (AML) by Donor Type in the US







Abbreviations - MRD: Matched related donor; MUD: Matched unrelated donor; Haplo: Haploidentical donor (includes all mismatched related donors); MMUD: Mismatched unrelated donor; CB: Cord blood

## Number of Allogeneic HCTs for Acute Lymphoblastic Leukemia (ALL) by Donor Type in the US





#### HSCT Survival and NRM over the years



Biol Blood Marrow Transplant 2020 Jul;26(7):1247-1256.





Acute GVHD

- Historically, occurs around the time of engraftment to day 100
- Classic aGVHD
- Persistent, recurrent or late aGVHD occurs after day 100
- Incidence of 30% to 50% in MSD



## **Glucksberg Criteria**

		CLINICAL STA	GING	
Stage	SKIN	LIVER (bilirubin)	GUT (output)	
0	No rash	<2 mg/dL	<50ml/day or nausea or vomiting	
I	Maculopapular rash, <25% BSA	2-3 mg/dL	500-999ml/day	
11	Maculopapular rash, 25-50% BSA	3.1-6 mg/dL	1000-1500ml/day	
111	Maculopapular rash, >50% BSA	6.1-15 mg/dL	>1500ml/day	$\begin{pmatrix} 4y_2 \\ y_6 \end{pmatrix} = \begin{pmatrix} 4y_2 \\ y_6 \end{pmatrix} \begin{pmatrix} 4y_2 \\ y_6 \end{pmatrix} \begin{pmatrix} 4y_2 \\ y_6 \end{pmatrix} \begin{pmatrix} 4y_2 \\ y_6 \end{pmatrix}$
IV	General erythema and bullous formation	>15 mg/dL	severe cramping +/- ileus	
	CLINICAL G	RADING		(1) 9% 9% (1) (1) (1) 9% 9% (1)
Grade	SKIN	LIVER	GUT	
1	Stage I-II			
2	Stage III or	Stage I or	Stage I	
3		Stage II-III or	Stage II-IV	
4	Stage IV or	Stage IV		معطوط معطوط معطوط مسلم المستك Anterior Posterior





- Multisystem immunologic disorder
- Chronic GVHD remains the leading cause of late morbidity and mortality
- Occurs in 30-70% of patient
- Starts later than aGVHD, about day 100 (oversimplification)





- Mechanisms not well understood ? induced by donor T cells, impaired T regulatory cell function, T and B cell homeostasis
- Can develop de novo, following resolution of GVHD, or as an extension of aGVHD
- Has some features of autoimmune disease





- Previous acute GVHD
- Age of recipient
- HLA mismatched donor/ unrelated donor
- Gender mismatched graft
- Parous female donor
- History of acute inflammation





- Classic GVHD
- Overlap Syndrome

Early Recognition is key\*\*\*\*



#### 2014 Diagnosis and Staging Working Group

Table 1

Signs and symptoms of chronic GVHD

ORGAN OR SITE		STIC at to establish osis of chronic		ronic GVHD, but t alone to establish a	OTHEI FEATU UNCL/ ENTIT	JRI ASS	SIFIED	COMM (Seen wi acute an chronic	ith both ad
Skin	•	Poikiloderma	•	Depigmentation	•		Sweat impairment	•	Erythema
	•	Lichen planus-like features	•	Papulosquamous lesions	•		Ichthyosis	•	Maculopapular rash
	•	Sclerotic features					Keratosis pilaris	•	Pruritus
	•	Morphea-like features			•		Hypopigmentation		
	•	Lichen sclerosus-like features			•		Hyperpigmentation		
Nails				Dystrophy					
			•	Longitudinal ridging, splitting or brittle features					
			•	Onycholysis					
			•	Pterygium unguis					
			•	Nail loss (usually symmetric, affects most nails)					
Scalp and Body Hair				New onset of scarring or non- scarring scalp alopecia, (after recovery from chemoradiotherapy) Loss of body hair Scaling			Thinning scalp hair, typically patchy, coarse or dull (not explained by endocrine or other causes), Premature gray hair		
Mouth		Lichen planus-like changes		Xerostomia					Gingivitis
			•	Mucoceles					Mucositis
			•	Mucosal atrophy					Erythema
			•	Ulcers					Pain
			•	Pseudomembranes					
Eyes			•	New onset dry, gritty, or painful eyes	:		Photophobia Periorbital hyperpigmentation		

Biol Blood Marrow Transplant. 2015 March ; 21(3): 389-401

ORGAN OR SITE	DIAGNOSTIC (Sufficient to establish the diagnosis of chronic GVHD)	DISTINCTIVE <sup>*</sup> (Seen in chronic GVHD, but insufficient alone to establish a diagnosis)	OTHER FEATURES OR UNCLASSIFIED ENTITIES <sup>**</sup>	COMMON <sup>***</sup> (Seen with both acute and chronic GVHD)
		<ul> <li>Cicatricial conjunctivitis</li> </ul>	<ul> <li>Blepharitis (erythema of the eye lids with edema)</li> </ul>	
		<ul> <li>Keratoconjunctivitis sicca</li> </ul>	with edema)	
		<ul> <li>Confluent areas of punctate keratopathy</li> </ul>		
ienitalia	Lichen planus-like features	Erosions		
	<ul> <li>Lichen sclerosus-like features</li> </ul>	<ul> <li>Fissures</li> </ul>		
		Ulcers		
Females	<ul> <li>Vaginal scarring or clitoral/ labial agglutination</li> </ul>			
Males	<ul> <li>Phimosis or urethral/meatus scarring or stenosis</li> </ul>			
GI Tract	Esophageal web		Exocrine pancreatic insufficiency	Anorexia
	<ul> <li>Strictures or stenosis in the</li> </ul>			Nausea
	upper to mid third of the esophagus			<ul> <li>Vomiting</li> </ul>
				Diarrhea
				<ul> <li>Weight loss</li> </ul>
				<ul> <li>Failure to thrive (infants and children</li> </ul>
.iver				<ul> <li>Total bilirubin, alkaline phosphatase &gt; 2 × upper limit of normal</li> </ul>
				<ul> <li>ALT&gt; 2× upper limit of normal</li> </ul>
ung	<ul> <li>Bronchiolitis obliterans diagnosed with lung biopsy</li> </ul>	<ul> <li>Air trapping and bronchiectasis on chest CT</li> </ul>	<ul> <li>Cryptogenic organizing pneumonia (COP)<sup>†</sup></li> </ul>	
	<ul> <li>Bronchiolitis obliterans syndrome (BOS)<sup>#</sup></li> </ul>		<ul> <li>Restrictive lung disease<sup>†</sup></li> </ul>	



ORGAN OR SITE	DIAGNOSTIC (Sufficient to establish the diagnosis of chronic GVHD)	DISTINCTIVE <sup>*</sup> (Seen in chronic GVHD, but insufficient alone to establish a diagnosis)	OTHER FEATURES OR UNCLASSIFIED ENTITIES <sup>**</sup>	COMMON <sup>***</sup> (Seen with both acute and chronic GVHD)
Muscles, Fascia, Joints	<ul> <li>Fasciitis</li> <li>Joint stiffness or contractures secondary to fasciitis or sclerosis</li> </ul>	<ul> <li>Myositis or polymyositis<sup>††</sup></li> </ul>	<ul> <li>Edema</li> <li>Muscle cramps</li> <li>Arthralgia or arthritis</li> </ul>	
Hematopoietic and Immune			<ul> <li>Thrombocytopenia</li> <li>Eosinophilia</li> <li>Lymphopenia</li> <li>Hypo- or hyper-gammaglobulines</li> <li>Autoantibodies (AIHA, ITP)</li> <li>Raynaud's phenomenon</li> </ul>	nia
Other			<ul> <li>Pericardial or pleural effusions</li> <li>Ascites</li> <li>Peripheral neuropathy</li> <li>Nephrotic syndrome</li> <li>Myasthenia gravis</li> <li>Cardiac conduction abnormality or cardiomyopathy</li> </ul>	ъг



	SITE SCORING							
	0	1		2	3			
PS (KPS)	100%	80-90%		60-70%	<60%			
Skin (BSA)	No sxs	<18% and no sclerotic features	19-5	0% or sclerotic	>50% or hidebound sclerotic or impaired mobility			
Mouth	No sxs	No limitations	Partial I	imits on PO intake	Major limitation of PO intake			
Eyes	No sxs	Not affecting ADL	Partia	Ily affecting ADL	Majorly affecting ADL			
GI	No sxs	<5% wt loss	5-	15% wt loss	>15% wt loss, or requiring esophageal dilation			
Liver	Normal LFT (bili, AP, AST, ALT)	< 2x ULN		2-5x ULN	>5x ULN			
Lungs	No sxs and FEV1 > 80%	FEV1 60-79%	F	EV1 40-59%	FEV1 <39%			
Joints & Fascia	No sxs	Mild tightness not affecting ADL	Tightness or contractures + mild/mod limitation of ADL		Contractures + decrease in ROM + limitation of ADL			
Genital tract	No sxs	No effect on coitus or exam	Moderate signs on exam and mild dyspareunia		Advanced signs on exam and severe pain with coitus			
		OVERALL SCC	DRE					
		Involved Sites	Max score					
	MILD	1-2	1					
		≥ 3	1					
	MODERATE	1	2					
		Lung	1					
	SEVERE		≥1	<u>3</u> ≥2				
		Lung	22					



Severity of Disease Correlates with Survival

2 year overall survival

Mild cGVHD – 97% Moderate cGVHD – 86% Severe cGVHD – 62%





- symptom burden reduction
- improvement of quality of life
- prevention of progression and inflammatory activity
- prevention of fibrosis and disability
- preservation of response to allow for withdrawal of immunosuppression
- repair and modulation of the immune system
- improvement of chronic GVHD





- Mainstay/1<sup>st</sup> line remains corticosteroids
- Ibrutinib

Ruxolitinib

• Belumosudil

On August 2<mark>, 2017, the U.S. Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. This is the first FDA-approved therapy for the treatment of cGVHD.</mark>

On September 22, 2021, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

• Site-specific Treatment \*\*\*\*



## More Treatments to Look Forward to....

- Itacitinib
- Abatacept
- Axalitinib
- Baricitinib
- Leflunomide
- Acalabrutinib
- Glasdegib
- Ofatumumab



Tissue Organs	Complications	Procedure	Timing
Immune System	Infections	PCP prophylaxis Immunizations Endocarditis - AHA	For at least 6 month 6, 12 months, Annually As recommended
Ocular	Cataracts Sicca Syndrome	Ophthalmologic examination	6, 12 months, Annually
Oral	Sicca Syndrome Caries/Periodontal disease Oral Cancer	Dental Assessment	6, 12 months, Annually
Respiratory	IPS COP BOOP Sino-pulmonary ifx	PFTs Radiologic studies	6, 12 months, Annually /Depending on symptoms

\* Frequency affected by presence of GVHD, being on steroids, use of TBI



Tissue Organs	Complications	Procedure	Timing
Cardiovascular	Cardiomyopathy CHF CAD PAD CVD	EKG ECHO Lipid profile FBG	6, 12 months, Annually/Depending on symptoms
Liver	GVHD Hep B/C Iron Overload	LFTs Hep B/C viral load Ferritin ( if multiple tranfusions), Imaging ( if needed)	6, 12 months, Annually/ Depending on symptoms
GU	CKD UTI Bladder Dysfunction	BUN Urine Protein Serum Cr	6, 12 months, Annually/Depending on symptoms



Tissue Organs	Complications	Procedure	Timing		
Muscle and connective tissue	Myopathy Fasciitis/Scleroderm a Polymyositis	Physical Activity ROM	6, 12 months, Annually		
Mucocutaneous	Cutaneous Sclerosis Genital GVHD	Skin Exams Pelvic Exams	6, 12 months, Annually		
Skeletal	Osteopenia/Osteop orosis Avascular necrosis	DEXA (women/all allo-HCT patients) MRI	12 months, Annually /Depending on symptoms		
CNS	Neuropsychological /Cognitive defects Peripheral Neuropathy Late Infections	Neuropsych testing *MRI	12 months, Annually /Depending on symptoms		
NM					



	Tissue Organs	Complications	Procedure	Timing	
	Endocrinology	Hypothyroidism Hypogonadism Hypoadrenalism Growth Retardation	TSH FSH/LH /Testosterone Growth Velocity	12 months, Annually /Depending on symptoms	
	Psychosocial and Sexual health	Anxiety Depression Fatigue Sexual Dysfunction	Mental dysfunction *Query Sexual health	6 /12 months, Annually/ Depending on Symptoms	
	Fertility	Infertility	FSH/LH Reproductive Health referral	12 months, Annually /Depending on symptoms	
	General	Secondary malignancies	Screening guidelines	6/12 months, Annually /Depending on symptoms NMDP guidelines	



## Thank you!